Dashboard
1
With ROE of 10.11%, it has a very attractive valuation with a 0.83 Price to Book Value
- Over the past year, while the stock has generated a return of 13.19%, its profits have risen by 26.1% ; the PEG ratio of the company is 0.3
- At the current price, the company has a high dividend yield of 2.7
Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,704 Million (Large Cap)
8.00
NA
2.73%
-0.03
10.11%
0.83
Revenue and Profits:
Net Sales:
1,572 Million
(Quarterly Results - Jun 2025)
Net Profit:
240 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.11%
0%
2.11%
6 Months
14.69%
0%
14.69%
1 Year
13.19%
0%
13.19%
2 Years
25.66%
0%
25.66%
3 Years
-17.63%
0%
-17.63%
4 Years
-14.64%
0%
-14.64%
5 Years
0%
0%
0.0%
Guobang Pharma Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Guobang Pharma Hits Day High with Strong Intraday Performance, Up 3.95%
Guobang Pharma saw a significant rise on October 13, 2025, contrasting with a decline in the China Shanghai Composite. The company has shown gains over the past week and year, although it lags behind the index in longer-term performance. Key financial metrics indicate a strong position in the market.
Read More Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.51%
EBIT Growth (5y)
-0.07%
EBIT to Interest (avg)
41.72
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.02
Sales to Capital Employed (avg)
0.59
Tax Ratio
11.75%
Dividend Payout Ratio
43.31%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.80%
ROE (avg)
10.18%
Valuation key factors
Factor
Value
P/E Ratio
8
Industry P/E
Price to Book Value
0.83
EV to EBIT
7.26
EV to EBITDA
4.80
EV to Capital Employed
0.83
EV to Sales
1.08
PEG Ratio
0.32
Dividend Yield
2.73%
ROCE (Latest)
11.39%
ROE (Latest)
10.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
1,571.70
1,541.30
1.97%
Operating Profit (PBDIT) excl Other Income
385.10
302.20
27.43%
Interest
6.20
7.40
-16.22%
Exceptional Items
4.70
6.20
-24.19%
Consolidate Net Profit
239.70
205.80
16.47%
Operating Profit Margin (Excl OI)
170.60%
129.30%
4.13%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 1.97% vs 10.80% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 16.47% vs 27.12% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
5,844.20
5,313.30
9.99%
Operating Profit (PBDIT) excl Other Income
1,265.80
948.60
33.44%
Interest
32.60
27.50
18.55%
Exceptional Items
7.90
10.30
-23.30%
Consolidate Net Profit
780.60
610.00
27.97%
Operating Profit Margin (Excl OI)
143.00%
117.90%
2.51%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 9.99% vs -6.58% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 27.97% vs -33.74% in Dec 2023
About Guobang Pharma Ltd. 
Guobang Pharma Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






